Source: Health Products Regulatory Authority (IE) Revision Year: 2021 Publisher: Sanofi-Aventis Ireland Limited T/A SANOFI, Citywest Business Campus, Dublin 24, Ireland
Triapin 2.5mg/2.5mg prolonged release tablet.
Pharmaceutical Form |
---|
Triapin 2.5mg/2.5mg tablets are circular (diameter approx 9 mm), apricot coloured, biconvex and engraved H/OD on one side and marked 2.5 on the other side. |
Each tablet contains 2.5 mg of felodipine and 2.5 mg of ramipril.
Excipient(s) with known effect:
Each tablet contains 52 mg lactose anhydrous. Each tablet contains 2.50 mg macrogolglycerol hydroxystearate (polyoxyl hydrogenated castor oil).
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Felodipine |
Felodipine is a vascular selective calcium antagonist, which lowers arterial blood pressure by decreasing systemic vascular resistance. Felodipine is effective in all grades of hypertension. |
|
Ramipril |
Ramiprilat, the active metabolite of the prodrug ramipril, inhibits the enzyme dipeptidylcarboxypeptidase I (synonyms: angiotensin-converting enzyme; kininase II). In plasma and tissue this enzyme catalyses the conversion of angiotensin I to the active vasoconstrictor substance angiotensin II, as well as the breakdown of the active vasodilator bradykinin. Reduced angiotensin II formation and inhibition of bradykinin breakdown lead to vasodilatation. |
|
Ramipril and Felodipine |
Both the calcium antagonist felodipine and the ACE inhibitor ramipril reduce blood pressure by dilation of the peripheral blood vessels. Calcium antagonists dilate the arterial beds while ACE inhibitors dilate both arterial and venous beds. Vasodilatation and thereby reduction of blood pressure may lead to activation of the sympathetic nervous system and the renin-angiotensin system. Inhibition of ACE results in decreased plasma angiotensin II. |
List of Excipients |
---|
Cellulose microcrystalline |
PVC/PVDC blisters: 10, 14, 15, 21, 28, 30, 50, 98 and 100 tablets.
Not all pack sizes may be marketed.
Sanofi-Aventis Ireland Limited T/A SANOFI, Citywest Business Campus, Dublin 24, Ireland
PA0540/082/001
Date of first authorisation: 13 July 1998
Date of lastest renewal: 19 September 2007
Drug | Countries | |
---|---|---|
TRIAPIN | Germany, Spain, Croatia, Ireland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.